Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.
NCT ID: NCT02321839
Last Updated: 2019-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
78 participants
INTERVENTIONAL
2014-01-31
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
NCT01831947
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
NCT01780935
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
NCT02328209
Ranibizumab Treatment for Age-Related Macular Degeneretion
NCT02158624
Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
NCT02843490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intraviteal Ranibizumab 0.5mg
Intraviteal Ranibizumab 0.5mg
Intraviteal Ranibizumab 0.5mg
Intraviteal Ranibizumab 0.5mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intraviteal Ranibizumab 0.5mg
Intraviteal Ranibizumab 0.5mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female of aged 50 years or older
* Typical AMD and PCV patients
* BCVA of 24 letters or over
Exclusion Criteria
* The existence of subretinal hemorrhage area constituting ≥50% of total lesion area
* The existence of scar or fibrosis area constituting ≥50% of total lesion area
* The existence of RPE tear
* Prior treatment for wet AMD
* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
* The pregnant or lactating woman
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Nagoya City University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuichiro Ogura
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuichiro Ogura
Role: STUDY_CHAIR
Nagoya City Univsersity
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sugita Eye Hospital
Nagoya, Aichi-ken, Japan
Nagoya City Univsersity
Nagoya, Aichi-ken, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kato A, Yasukawa T, Sugita I, Yoshida M, Nozaki M, Hirano Y, Kondo J, Abe T, Sugita K, Okita T, Morita H, Takase N, Ogura Y. Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration. Adv Ther. 2022 Mar;39(3):1403-1416. doi: 10.1007/s12325-022-02052-1. Epub 2022 Feb 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAENCU001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.